APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Medicine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Growth and Trends Forecast to 2032

Report ID 174029910128 December 202598 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Medicine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Medicine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine include Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Arterial Hypertension (PAH) Medicine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Arterial Hypertension (PAH) Medicine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Arterial Hypertension (PAH) Medicine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Arterial Hypertension (PAH) Medicine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pulmonary Arterial Hypertension (PAH) Medicine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Arterial Hypertension (PAH) Medicine Market by Company

Actelion Pharmaceuticals

Gilead Sciences

United Therapeutics Corporation

Pfizer

Eli Lilly

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type

Calcium Channel Blockers

Novel Targeted Drugs

Other

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application

Secondary Pulmonary Hypertension (SPH)

Primary Pulmonary Hypertension (PPH)

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pulmonary Arterial Hypertension (PAH) Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Calcium Channel Blockers Table 2. Major Company of Novel Targeted Drugs Table 3. Major Company of Other Table 4. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type (2021-2026) Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type (2021-2026) Table 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2021-2026) & (US$/Unit) Table 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2027-2032) & (K Units) Table 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type (2027-2032) Table 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2027-2032) & (US$ Million) Table 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type (2027-2032) Table 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2027-2032) & (US$/Unit) Table 15. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 16. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 18. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 22. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (US$ Million) Table 25. Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends Table 26. Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers Table 27. Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges Table 28. Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints Table 29. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Company (2021-2026) Table 31. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Company (2021-2026) & (K Units) Table 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Company (2021-2026) Table 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Pulmonary Arterial Hypertension (PAH) Medicine Major Company Production Sites and Headquarters Table 36. Global Pulmonary Arterial Hypertension (PAH) Medicine Company, Product Type & Application Table 37. Global Pulmonary Arterial Hypertension (PAH) Medicine Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Pulmonary Arterial Hypertension (PAH) Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026) & (K Units) Table 42. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Region (2021-2026) Table 43. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026) & (US$ Million) Table 44. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Region (2021-2026) Table 45. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2027-2032) & (K Units) Table 47. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Region (2027-2032) Table 48. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2027-2032) & (US$ Million) Table 49. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Region (2027-2032) Table 50. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 53. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application (2021-2026) Table 54. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 55. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application (2021-2026) Table 56. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2021-2026) & (US$/Unit) Table 57. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2027-2032) & (K Units) Table 58. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application (2027-2032) Table 59. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2027-2032) & (US$ Million) Table 60. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application (2027-2032) Table 61. Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2027-2032) & (US$/Unit) Table 62. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 63. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 65. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 69. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (US$ Million) Table 72. Actelion Pharmaceuticals Company Information Table 73. Actelion Pharmaceuticals Business Overview Table 74. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 76. Actelion Pharmaceuticals Recent Development Table 77. Gilead Sciences Company Information Table 78. Gilead Sciences Business Overview Table 79. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 81. Gilead Sciences Recent Development Table 82. United Therapeutics Corporation Company Information Table 83. United Therapeutics Corporation Business Overview Table 84. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 86. United Therapeutics Corporation Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 91. Pfizer Recent Development Table 92. Eli Lilly Company Information Table 93. Eli Lilly Business Overview Table 94. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 96. Eli Lilly Recent Development Table 97. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 98. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 99. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 100. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032) & (K Units) Table 101. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Country (2027-2032) Table 102. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026) & (US$ Million) Table 104. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country (2021-2026) Table 105. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Share Forecast by Country (2027-2032) Table 107. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 108. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 109. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 110. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032) & (K Units) Table 111. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Country (2027-2032) Table 112. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026) & (US$ Million) Table 114. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country (2021-2026) Table 115. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Share Forecast by Country (2027-2032) Table 117. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 119. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 120. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032) & (K Units) Table 121. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026) & (US$ Million) Table 124. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country (2021-2026) Table 125. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Share Forecast by Country (2027-2032) Table 127. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 129. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 130. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032) & (K Units) Table 131. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Country (2027-2032) Table 132. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026) & (US$ Million) Table 134. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country (2021-2026) Table 135. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Share Forecast by Country (2027-2032) Table 137. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 140. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032) & (K Units) Table 141. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026) & (US$ Million) Table 144. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country (2021-2026) Table 145. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Share Forecast by Country (2027-2032) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List Table 150. Pulmonary Arterial Hypertension (PAH) Medicine Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Medicine Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2032) & (K Units) Figure 5. Calcium Channel Blockers Image Figure 6. Global Calcium Channel Blockers Sales YoY Growth (2021-2032) & (K Units) Figure 7. Novel Targeted Drugs Image Figure 8. Global Novel Targeted Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Type 2025 VS 2032 Figure 13. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type in 2025 Figure 14. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type in 2025 Figure 15. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type in 2025 Figure 16. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type in 2025 Figure 19. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Secondary Pulmonary Hypertension (SPH) Image Figure 26. Global Secondary Pulmonary Hypertension (SPH) Sales YoY Growth (2021-2032) & (K Units) Figure 27. Primary Pulmonary Hypertension (PPH) Image Figure 28. Global Primary Pulmonary Hypertension (PPH) Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application 2025 VS 2032 Figure 31. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application in 2025 Figure 32. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application in 2025 Figure 33. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application in 2025 Figure 34. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application in 2025 Figure 37. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share in Value by Application in 2025 Figure 41. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel Blockers
  • Novel Targeted Drugs
  • Other
Applications
  • Secondary Pulmonary Hypertension (SPH)
  • Primary Pulmonary Hypertension (PPH)
Companies covered
  • Actelion Pharmaceuticals
  • Gilead Sciences
  • United Therapeutics Corporation
  • Pfizer
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pulmonary Arterial Hypertension (PAH) Medicine Market by Type
  6. 1.3.1 Calcium Channel Blockers
  7. 1.3.2 Novel Targeted Drugs
  8. 1.3.3 Other
  9. 1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Type
  10. 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2026)
  2. 3.2 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2026)
  3. 3.3 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Price (2021-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Major Company Production Sites & Headquarters
  6. 3.6 Global Pulmonary Arterial Hypertension (PAH) Medicine Company, Product Type & Application
  7. 3.7 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Arterial Hypertension (PAH) Medicine Tier 1, Tier 2, and Tier 3
4 Pulmonary Arterial Hypertension (PAH) Medicine Regional Status and Outlook
  1. 4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Region
  3. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Region
  7. 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pulmonary Arterial Hypertension (PAH) Medicine by Application
  1. 5.1 Pulmonary Arterial Hypertension (PAH) Medicine Market by Application
  2. 5.1.1 Secondary Pulmonary Hypertension (SPH)
  3. 5.1.2 Primary Pulmonary Hypertension (PPH)
  4. 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Application
  5. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Actelion Pharmaceuticals
  2. 6.1.1 Actelion Pharmaceuticals Company Information
  3. 6.1.2 Actelion Pharmaceuticals Business Overview
  4. 6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  6. 6.1.5 Actelion Pharmaceuticals Recent Developments
  7. 6.2 Gilead Sciences
  8. 6.2.1 Gilead Sciences Company Information
  9. 6.2.2 Gilead Sciences Business Overview
  10. 6.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  12. 6.2.5 Gilead Sciences Recent Developments
  13. 6.3 United Therapeutics Corporation
  14. 6.3.1 United Therapeutics Corporation Company Information
  15. 6.3.2 United Therapeutics Corporation Business Overview
  16. 6.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  18. 6.3.5 United Therapeutics Corporation Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Eli Lilly
  26. 6.5.1 Eli Lilly Company Information
  27. 6.5.2 Eli Lilly Business Overview
  28. 6.5.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  30. 6.5.5 Eli Lilly Recent Developments
7 North America by Country
  1. 7.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  2. 7.1.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  4. 7.1.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
  6. 7.2.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026)
  8. 7.2.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  2. 8.1.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  4. 8.1.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
  6. 8.2.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  2. 9.1.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
  6. 9.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  2. 10.1.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  4. 10.1.3 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
  6. 10.2.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026)
  8. 10.2.3 South America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country
  2. 11.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country
  6. 11.2.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Analysis
  2. 12.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process
  7. 12.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
  10. 12.2.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst